A Research Study to Evaluate the Safety and Effectiveness of MK0686 for the Treatment of Postherpetic Neuralgia (Also Known as PHN or Post Shingles Pain) (0686-005)

Proprietary Information - Exploratory (Non-confirmatory) Trial

NCT00282763•Merck Sharp & Dohme LLC

Summary

The purpose of this Study is to test the Safety and Effectiveness of MK0686 in relieving neuropathic (chronic) pain as experienced by patients with Postherpetic Neuralgia (Also Know as PHN or Post Shingles Pain). This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of postherpetic neuralgia with pain having lasted at least 6 months
•Able to complete study questionnaires, patient diary, and comply with daily study medication
•Patient is not satisfied with current treatment for pain control

Exclusion Criteria

•Pregnant or nursing female
•History of evidence of a condition that in the opinion of the investigator, may interfere with the study results (e.g., diabetic neuropathy of fibromyalgia) or pose undue risk to undergo the course of medication required by the study (e.g., unstable heart disease, morbid obesity, kidney or liver disease)

Key Dates

Start Date

December 1, 2005

Primary Completion Date

August 1, 2006

Completion Date

August 1, 2006

Last Updated

November 23, 2015

Enrollment

ACTUAL participants

Conditions

Neuralgia, Postherpetic

Interventions

MK0686

DRUG

Safety and Preliminary Efficacy of MK0759 in Postherpetic Neuralgia (PHN)(0759-004)

NCT00245544

Neuralgia, Postherpetic

View study

COMPLETEDPHASE1

Neuropathic Pain Syndrome Patient Study (MK-0000-072)

NCT00570310

Neuralgia, PostherpeticDiabetic Neuropathy+2 more

View study

COMPLETED

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 23, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Research Study to Evaluate the Safety and Effectiveness of MK0686 for the Treatment of Postherpetic Neuralgia (Also Known as PHN or Post Shingles Pain) (0686-005)

Inclusion Criteria

Exclusion Criteria

Safety and Preliminary Efficacy of MK0759 in Postherpetic Neuralgia (PHN)(0759-004)

Neuropathic Pain Syndrome Patient Study (MK-0000-072)

A 16 Week Study Evaluating Levetiracetam in the Treatment of Post Herpetic Neuralgia (PHN)

A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment

PH-797804 Versus Placebo For The Treatment Of Neuropathic Pain Associated With Post-Herpetic Neuralgia

Effect of Opioids in Neuropathic Pain in Postherpetic Patients